psalexa
logo

Peanut Allergy Therapeutics Pipeline Analysis

Peanut Allergy Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: March 2018
Report Code: LS11395
Available Format:
Pages: 88

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Peanut allergy is one of the most common type of allergies caused by a legume, known as peanut. The symptoms of the disease include, hives, nausea, stomach cramps, tightness in throat, tingling sensation in or around oral cavity, and rhinorrhea. It has been observed that the patients suffering with asthma and eczema are more likely to get allergy from peanuts. In severe conditions, drop in blood pressure, fainting, swelling in throat, and blockage of airway can also occur.

 

PEANUT ALLERGY DRUG CANDIDATES IN DEVELOPMENT (2018)

PEANUT ALLERGY DRUG CANDIDATES IN DEVELOPMENT

 

Majority of drug candidates in the pipeline are being manufactured through advanced technologies developed by various educational institutes or companies. Rise in the number of patents approvals and advancements in technologies are the major factors driving the growth of the pipeline.

Some of the other factors enhancing the pipeline growth include; positive clinical as well as Pre-Clinical results of various drug candidates and support from various health organizations such as National Institutes of Health and United States Department of Defense, and educational institutes.

Pipeline Analysis

As of March 2018, the peanut allergy therapeutics pipeline comprises of 19 drug candidates in different stages of development. Currently there is no approved drug for the treatment of peanut allergy, leading to a a large unmet need in the its therapeutic pipeline. The lack of any approved medication for the treatment of peanut allergy in the market means that whosoever gets their pipeline drug in the market first, would receive first mover advantage.

Competitive Landscape

Some of the key players involved in the development of peanut allergy therapeutics include Aimmune Therapeutics Inc., DBV Technologies S.A., and AnaptysBio Inc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry